PDCD1 and neoplasm: Triple ICB resulted in a decreased tumor growth and enhanced response (11/13 vs. 6/13) to ICB therapy when compared with ICB targeting PD-1 and CTLA-4 only (Fig. 5d, Supplementary Fig. 11f).